Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: The onset 2 trial

Diabetes Care

Volumn 40, Issue 7, 2017, Pages 951-957

  Bowering, Keith ^a   Case, Christopher ^b   Harvey, John ^c   Reeves, Michael ^d   Sampson, Michael ^e   Strzinek, Robert ^f   Bretler, Ditte Marie ^g   Bang, Rikke Beck ^g   Bode, Bruce W ^h  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Jefferson City Medical Group   (United States)

^c BANGOR UNIVERSITY   (United Kingdom)

^d Diabetes Clinical Trials   (United States)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f Protenium Clinical Research   (United States)

^g NOVO NORDISK A S   (Denmark)

^h Atlanta Diabetes Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ALGORITHM; BODY WEIGHT; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; BIOASSAY; CLINICAL TRIAL; MEAL; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN GLARGINE; MALE; MEALS; METFORMIN; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 85021098134     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1770     Document Type: Conference Paper

References (30)

1. Inzucchi SE, BergenstalRM, Buse JB, et al.Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
2. Ceriello A. The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract 2010;64: 1705-1711
3. International Diabetes Federation. Global Guideline for Type 2 Diabetes. Brussels, Belgium, International Diabetes Federation [article online], 2012. Available from http://www.idf.org/guidelinetype-2-diabetes. Accessed 29 Jun 2016
4. Monnier L, Colette C, Dejager S, Owens DR. "Mild dysglycemia" in type 2 diabetes: to be neglected or not? J Diabetes Complications 2015;29: 451-458
5. Peter R, Dunseath G, Luzio SD, Chudleigh R, Choudhury SR, Owens DR. Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with type 2 diabetes. Diabet Med 2009;26:974-980
6. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next? Diabetes Metab Res Rev 2007;23:257-264
7. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol 2012;6:728-742
8. Home PD. Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab 2015;17:1011-1020
9. Buckley ST, Kildegaard J, Høiberg-Nielsen R, et al.Mechanistic analysis into themode of action of niacinamide in faster-acting insulin aspart. Diabetes Technol Ther 2016;18(Suppl. 1):A291
10. Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet 2017;56:551-559
11. Russell-Jones D, Bode BW, De Block C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care 2017;40:943-950
12. Rodbard HW, Tripathy D, Vidrio VelázquezM, Demissie M, Can Tamer S, Piletič M. Adding fastacting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomised, 18-week, openlabel, phase 3 trial (onset 3). Diabetes ObesMetab 27 March 2017 [Epub ahead of print] DOI: 10.1111/dom.12955
13. World Medical Association. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Amended by the 59th WMA General Assembly, Seoul 2008
14. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practise [article online], 1996. Available from: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf. Accessed 27 July 2016
15. Novo Nordisk. NovoRapid (insulin aspart): Summary of Product Characteristics [article online]. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000258/WC500030372.pdf. Accessed 16 August 2016
16. Magee MF, Reyes-Castano, Nassar CM. Insulin therapy in adultswith type 1 diabetesmellitus. In Type 1 Diabetes in Adults: Principles and Practice. Jabbour S, Stephens EA, Eds. Boca Raton, CRC Press, 2007, p. 67-108
17. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-1395
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
20. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
21. Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2016;51:417-428
22. Dungan KM, Buse JB, Largay J, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006;29:1214-1219
23. Wang Y, Zhang YL,Wang YP, Lei CH, Sun ZL. A study on the association of serum1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China. Diabetes Metab Res Rev 2012;28:357-362
24. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne) 2013;4:37
25. Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetesmellitus. J Diabetes 2013;5: 482-491
26. King AB. Howmuch do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose monitoring. Endocr Pract 2010;16: 428-432
27. Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract 2008;14:1095-1101
28. van Dieren S, Czernichow S, Chalmers J, et al. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab 2012;14: 464-469
29. Home PD, Lindholm A, Riis A; European Insulin Aspart StudyGroup. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17: 762-770
30. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract 2011;17:727-736